GenFleet Therapeutics (Shanghai) Inc. (HKG:2595)
Hong Kong · Delayed Price · Currency is HKD 30.22
-0.92 (-2.95%)
At close: Feb 13, 2026
GenFleet Therapeutics (Shanghai) Company Description
GenFleet Therapeutics (Shanghai) Inc. operates as a biopharmaceutical company that focuses on developing novel treatment options in the fields of oncology that cover different lines of treatments of multiple solid tumors, as well as autoimmune and inflammatory diseases.
The company’s products include GFH925, help for the treatment of advanced non-small cell lung cancer, and GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C.
The company was incorporated in 2017 and is based in Shanghai, China.
GenFleet Therapeutics (Shanghai) Inc.
| Country | China |
| Founded | 2017 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 94 |
| CEO | Jiong Lan |
Contact Details
Address: Floors 2, 3, 4, and 5 Building 8 Shanghai, 201203 China | |
| Phone | 86 21 6882 1388 |
| Website | genfleet.com |
Stock Details
| Ticker Symbol | 2595 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jiong Lan | Chief Executive Officer |